• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Aptinyx Inc (NQ: APTX )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, May 18, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Aptinyx Inc

    < Previous 1 2 Next >
    Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx to Present at the SVB Securities Global Biopharma Conference
    From Aptinyx Inc.
    Via Business Wire
    Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights
    From Aptinyx Inc.
    Via Business Wire
    Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx to Participate in H.C. Wainwright 1st Annual Mental Health Conference
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx to Participate in H.C. Wainwright Global Investment Conference
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD at the 2022 American Psychiatric Association Annual Meeting
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Progress
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx Presents Preclinical Data on NYX-783 in Models of PTSD at 2022 Society of Biological Psychiatry Annual Meeting
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx Announces Publication in Molecular Psychiatry Demonstrating Reduction of Spontaneous Recovery of Fear with NYX-783
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx Reports Fourth Quarter and Full Year 2021 Results and Highlights
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx Hosts Virtual Portfolio Review Event to Showcase NYX-2925 in Chronic Pain and Provide Update on Clinical Development Programs
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx to Present at the SVB Leerink 11th Annual Global Healthcare Conference
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx Announces Formation of Scientific Advisory Board
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx Highlights Key Goals and Anticipated Development Milestones for 2022
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx to Host Virtual Portfolio Review Event on February 9th, 2022
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx Initiates Phase 2b Study of NYX-783 in Patients with Post-Traumatic Stress Disorder
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx to Present at the 40th Annual J.P. Morgan Healthcare Conference
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
    From Aptinyx Inc.
    Via Business Wire
    Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights
    From Aptinyx Inc.
    Via Business Wire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.